Tech Center 2100 • Art Units: 1672 1687 2187
This examiner grants 35% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17250814 | METHODS AND SYSTEMS FOR MONITORING ORGAN HEALTH AND DISEASE | Non-Final OA | Illumina, Inc. |
| 17135826 | METHODS AND SYSTEMS FOR ANALYSIS OF CTCF BINDING REGIONS IN CELL-FREE DNA | Final Rejection | GUARDANT HEALTH, INC. |
| 17376096 | METHODS, CIRCUITS, AND ARTICLES OF MANUFACTURE FOR SEARCHING WITHIN A GENOMIC REFERENCE SEQUENCE FOR QUERIED TARGET SEQUENCE USING HYPER-DIMENSIONAL COMPUTING TECHNIQUES | Final Rejection | The Regents of the University of California |
| 17078137 | Systems and Methods for Auto-Inoculation in Seed Train and Production Processes | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | Non-Final OA | GENENTECH, INC. |
| 18583701 | HIGH DYNAMIC RANGE DIGITAL QUANTITATION OF TARGETS | Final Rejection | ENUMERIX, INC. |
| 17790725 | OPTIMIZATION APPARATUS, OPTIMIZATION METHOD, AND PROGRAM | Non-Final OA | NIPPON TELEGRAPH AND TELEPHONE CORPORATION |
| 17790869 | METHODS AND ARRANGEMENTS TO DESCRIBE DEFORMITY OF A BONE | Non-Final OA | Smith & Nephew Asia Pacific Pte. Limited |
| 17028303 | VARIANT CALLING USING MACHINE LEARNING | Final Rejection | MYRIAD WOMEN'S HEALTH, INC. |
| 18338488 | SYSTEMS AND METHODS FOR SEQUENCE DATA ALIGNMENT QUALITY ASSESSMENT | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 17153491 | INFORMATION ACQUISITION METHOD USING HEART AND LUNG SOUNDS | Non-Final OA | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION |
| 18747178 | DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTS | Final Rejection | Natera, Inc. |
| 18736229 | PROTEIN STRUCTURE SEARCH | Final Rejection | EvolutionaryScale, PBC |
| 17119606 | CANCER CLASSIFICATION USING PATCH CONVOLUTIONAL NEURAL NETWORKS | Non-Final OA | GRAIL, LLC |
| 18387311 | SYSTEMS AND METHODS FOR DERIVING AND OPTIMIZING CLASSIFIERS FROM MULTIPLE DATASETS | Non-Final OA | Inflammatix, Inc. |
| 17774464 | METHODS OF DETERMINING ATTRIBUTES OF THERAPEUTIC T CELL COMPOSITIONS | Non-Final OA | Juno Therapeutics, Inc. |
| 16968374 | BIOPROCESSING METHODS FOR CELL THERAPY | Final Rejection | Global Life Sciences Solutions USA LLC |
| 18340816 | SUBCUTANEOUS OUTPATIENT MANAGEMENT | Non-Final OA | Aseko, Inc. |
| 17776416 | Computational Platform To Identify Therapeutic Treatments For Neurodevelopmental Conditions | Non-Final OA | STALICLA SA |
| 17257660 | INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING SYSTEM, AND PROGRAM | Non-Final OA | Bayer CropScience K.K. |
| 17914731 | SYSTEMS AND METHODS FOR DISTINGUISHING PATHOLOGICAL MUTATIONS FROM CLONAL HEMATOPOIETIC MUTATIONS IN PLASMA CELL-FREE DNA BY FRAGMENT SIZE ANALYSIS | Non-Final OA | Memorial Sloan Kettering Cancer Center |
| 17780404 | MOLECULAR DATA STORAGE SYSTEMS AND METHODS | Non-Final OA | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. |
| 16975823 | Neoantigen Identification with Pan-Allele Models | Non-Final OA | Gritstone bio,Inc. |
| 17514269 | High-Capacity Storage of Digital Information in DNA | Non-Final OA | EUROPEAN MOLECULAR BIOLOGY LABORATORY |
| 16460051 | High-Capacity Storage of Digital Information in DNA | Final Rejection | EUROPEAN MOLECULAR BIOLOGY LABORATORY |
| 17796826 | SYSTEM AND METHOD FOR LEARNING TO GENERATE CHEMICAL COMPOUNDS WITH DESIRED PROPERTIES | Non-Final OA | 99ANDBEYOND INC. |
| 17860760 | Antibody Competition Model Using Hidden Variable Affinities | Non-Final OA | AbCellera Biologics Inc. |
| 17790183 | SYSTEM AND METHOD TO SELECT PHAGE THERAPY BASED ON TIME AND LOCATION | Non-Final OA | Adaptive Phage Therapeutics, LLC |
| 17436970 | METHOD AND SYSTEM FOR PATIENT-SPECIFIC PREDICTING OF CYCLIC LOADING FAILURE OF A CARDIAC IMPLANT | Final Rejection | FEops NV |
| 17432067 | METHOD FOR DETERMINING CONDITION PARAMETERS FOR PHOTODYNAMIC THERAPY AND PHOTODYNAMIC THERAPY APPARATUS | Final Rejection | OTSUKA ELECTRONICS CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy